{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:16:55Z","timestamp":1747196215873,"version":"3.40.5"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Acute ischemic stroke (AIS) in patients with non-valvular atrial fibrillation (AF) despite oral anticoagulation (OAC) is a complex and insufficiently investigated setting. Potential strategies range from maintaining the current OAC to changing the substance class. We have queried the specific treatment standards on German stroke units (SUs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>By means of a standardized online questionnaire via SurveyMonkey\u2122 (San Mateo, CA, USA), all clinical heads of German SUs were asked about their treatment standards in the following clinical situations: first AIS of an OAC-na\u00efve AF patient, AF patient with AIS despite administration of a vitamin K antagonist (VKA), AF patient with AIS despite administration of direct OAC (DOAC). In addition, the performance of specific coagulation tests in AF patients with AIS despite OAC was queried.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>160 (48%) clinical heads of German SU responded. Data from pivotal trials (84%), own experience with substances (71%), and side-effect profiles (66%) determine the initial DOAC prescription. In case of an AIS despite OAC, 83 and 18% would switch from VKA to DOAC under certain conditions and always, respectively. Half of respondents would switch from DOAC to VKA under certain conditions, while the other half would decline. 96% would switch to an alternative DOAC. The vast majority of those who made preconditions considered concomitant diseases (92, 90, and 81%, respectively). Few would consider infarct pattern (&lt;35%). 61% perform initial coagulation tests (only one-third substance-specific assessments); however, the majority do not use these to make further decisions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In the setting of an OAC-na\u00efve AF patient with AIS, established pivotal data are most respected. In the unclear setting of an AIS despite OAC, most respondents consider concomitant diseases and give preference to switching to a (different) DOAC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0264122","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T18:43:55Z","timestamp":1645123435000},"page":"e0264122","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units"],"prefix":"10.1371","volume":"17","author":[{"given":"Christian","family":"Fastner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Samartzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Kruska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2487-7205","authenticated-orcid":true,"given":"Angelika","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"8","key":"pone.0264122.ref001","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"PA Wolf","year":"1991","journal-title":"Stroke"},{"issue":"1","key":"pone.0264122.ref002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12883-017-0819-0","article-title":"Stroke unit care in germany: the german stroke registers study group (ADSR)","volume":"17","author":"S Hillmann","year":"2017","journal-title":"BMC Neurol"},{"issue":"3","key":"pone.0264122.ref003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline","volume":"4","author":"CJ Klijn","year":"2019","journal-title":"Eur Stroke J"},{"issue":"5","key":"pone.0264122.ref004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"9921","key":"pone.0264122.ref005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"CT Ruff","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"pone.0264122.ref006","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.25700","article-title":"Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation","volume":"87","author":"DJ Seiffge","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"pone.0264122.ref007","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0264122.ref008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0264122.ref009","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0264122.ref010","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0264122.ref011","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","article-title":"Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack","volume":"48","author":"CI Coleman","year":"2017","journal-title":"Stroke"},{"issue":"3","key":"pone.0264122.ref012","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1160\/TH17-10-0733","article-title":"Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation","volume":"118","author":"SH Hohnloser","year":"2018","journal-title":"Thromb Haemost"},{"issue":"11","key":"pone.0264122.ref013","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week","volume":"75","author":"BS Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"pone.0264122.ref014","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"KI Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"pone.0264122.ref015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CLEP.S290707","article-title":"Stroke Incidence and Death in Atrial Fibrillation Patients Newly Treated with Direct Oral Anticoagulants","volume":"13","author":"A Gabet","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"9","key":"pone.0264122.ref016","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092938","article-title":"Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants","volume":"9","author":"JC Purrucker","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0264122.ref017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2016.0393","article-title":"Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation","volume":"1","author":"B Freedman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"2","key":"pone.0264122.ref018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Y Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"pone.0264122.ref019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25917","article-title":"Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation","volume":"89","author":"TR Meinel","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"pone.0264122.ref020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.007","article-title":"Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants\u2019 Administration for Secondary Prevention of Stroke","volume":"27","author":"Y Kanai","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"19","key":"pone.0264122.ref021","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","article-title":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"40","author":"KL Wang","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"pone.0264122.ref022","first-page":"512","article-title":"Anticoagulation in patients with chronic kidney disease: Recommendations from the working group \"Heart-Kidney\" of the German Cardiac Society and the German Society of Nephrology","volume":"58","author":"G Schlieper","year":"2017","journal-title":"Internist (Berl)"},{"issue":"10","key":"pone.0264122.ref023","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/clc.23085","article-title":"Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk","volume":"41","author":"HS Bhatia","year":"2018","journal-title":"Clin Cardiol"},{"issue":"6","key":"pone.0264122.ref024","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1055\/s-0039-1683428","article-title":"Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study","volume":"119","author":"SH Hohnloser","year":"2019","journal-title":"Thromb Haemost"},{"key":"pone.0264122.ref025","first-page":"1695","article-title":"Adherence to oral anticoagulant therapy in secondary stroke prevention\u2014impact of the novel oral anticoagulants","volume":"9","author":"S Luger","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"pone.0264122.ref026","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/jnnp-2021-326166","article-title":"Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study","volume":"92","author":"S Yaghi","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"pone.0264122.ref027","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1161\/STROKEAHA.119.027275","article-title":"Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke","volume":"51","author":"K Tanaka","year":"2020","journal-title":"Stroke"},{"key":"pone.0264122.ref028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2020.10.011","article-title":"Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis","volume":"197","author":"S Mainbourg","year":"2021","journal-title":"Thromb Res"},{"issue":"19","key":"pone.0264122.ref029","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2018-04-791541","article-title":"Testing and monitoring direct oral anticoagulants","volume":"132","author":"JM Connors","year":"2018","journal-title":"Blood"},{"issue":"10117","key":"pone.0264122.ref030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"SS Anand","year":"2018","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T18:44:15Z","timestamp":1645123455000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264122"}},"subtitle":[],"editor":[{"given":"Nienke","family":"van Rein","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264122","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}